NovaBridge Biosciences: cash_and_equivalents
| Value | {"amount": 291506000, "concept": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "currency": "USD"} |
|---|---|
| Period | (as of 2023-12-31) |
| Status | current |
| Entity | NovaBridge Biosciences |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:00:48.227251+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/5c991d2b-e704-4a09-8c18-ae926996349b
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0000950170-25-050344Retrieved: 2026-08-19T18:00:48.227251+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001778016/cash-and-equivalents/2023-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/5c991d2b-e704-4a09-8c18-ae926996349b
History
- supersedes {"amount": 301616000, "concept": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "currency": "USD"} (evidence 0001104659-24-054452)